Objective To analyze the clinical value of lyophilized recombinant human brain natriuretic peptide(trade name:Xinhuosu)in patients with coronary heart disease and acute heart failure.Methods 60 patients with coronary heart disease and acute heart failure were divided into a control group and a study group according to the random numerical table,with 30 cases in each group.The control group was treated with isosorbide dinitrate,and the study group was treated with isosorbide dinitrate and Xinhuosu.The clinical therapeutic effect and the vital signs[diastolic blood pressure,systolic blood pressure,heart rate,N-terminal pro-brain natriuretic peptide(NT-proBNP)]before and after treatment were compared between the two groups.Results Compared with the control group(80.00%),the total effective rate of the study group(96.67%)was significantly higher,and the difference between groups was statistically significant(χ2=4.043,P<0.05).After treatment,the diastolic blood pressure,systolic blood pressure,heart rate and NT-proBNP levels in both groups were significantly lower than those before treatment;the study group had diastolic blood pressure of(83.11±2.13)mm Hg(1 mm Hg=0.133 kPa),systolic blood pressure of(108.37±4.62)mm Hg,heart rate of(82.16±1.74)beats/min,and NT-proBNP of(1251.39±46.23)pg/ml,which were significantly lower than(87.16±2.72)mm Hg,(123.28±4.19)mm Hg,(87.16±2.16)beats/min,and(1763.27±95.16)pg/ml in the control group;the difference between groups was statistically significant(P<0.05).Conclusion The application of Xinhuosu in the treatment of coronary heart disease combined with acute heart failure can effectively regulate the patient's heart function,promote the prognosis of patients,and improve the overall efficacy.It has high clinical application value,and is worth promoting.
关键词
冠心病/急性心力衰竭/冻干重组人脑利钠肽/临床价值
Key words
Coronary heart disease/Acute heart failure/Lyophilized recombinant human brain natriuretic peptide/Clinical value
维普
万方数据